世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧州の免疫組織化学市場予測 2018-2026年

EUROPE IMMUNOHISTOCHEMISTRY MARKET FORECAST 2018-2026

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2018年4月US$1,250
シングルユーザライセンス
81

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

サマリー

この調査レポートは欧州の免疫組織化学市場を分析・予測したInkwood Researchの市場調査報告書です。

Description

KEY FINDINGS
The European market for immunohistochemistry is developing at a CAGR of 7.88% over the forecasting period. Increased academic research funding was seen in the year 2017, especially in UK, France and Germany. Also, the technological expansion is proliferating the growth of the immunohistochemistry market in Europe.
MARKET INSIGHTS
The dominant countries in the Europe region are Germany, Russia, United Kingdom, France, Italy, Spain, and rest of Europe. The growing rate of cardiovascular disorders is helping the UK to sustain its leading position in the region. Germany is developing due to the growing cases of diabetes, making it the fastest growing country for immunohistochemistry market in Europe. The various products category available in the immunohistochemistry market are antibodies, equipment, reagents, and kits. Out of which, reagents dominate by holding the highest share in the product segment.
COMPETITIVE INSIGHTS
Histologix, Merck Millipore, Bio Sb, Cell Signaling Technology Inc., Agilent Technologies Inc., Siemens Ag Healthcare, Thermo Fisher Scientific Inc., Perkinelmer Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Abcam Plc, Abbott Laboratories, F. Hoffmann-La Roche Ag, and Biogenex are the key companies dominating the immunohistochemistry market.



目次

Table of Contents

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. REAGENTS PRODUCTS ARE GROWING AT A SIGNIFICANT RATE
3.2.2. DIAGNOSTICS IS MAJORLY USED APPLICATION IN THE MARKET
3.2.3. HOSPITALS AND DIAGNOSTIC LABORATORIES HOLDS THE LARGEST MARKET SHARE IN THE END-USERS MARKET
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. RISING CANCER INCIDENCE
4.1.2. TECHNOLOGICAL EXPANSIONS IN IN-VITRO DIAGNOSTIC COMMERCE
4.1.3. INCREASING HEALTHCARE SPENDING
4.1.4. GROWING POPULARITY OF POC TESTING
4.2. MARKET RESTRAINTS
4.2.1. INSURANCE COVERAGE AND REIMBURSEMENT ISSUES
4.2.2. LIMITATIONS OF CLOSED SYSTEMS
4.2.3. PRESENCE OF AN UNDIAGNOSED POPULATION
4.3. MARKET OPPORTUNITIES
4.3.1. USE OF BIOMARKERS FOR DISEASE DIAGNOSIS AND INCREASING EFFICIENCY
4.3.2. PARADIGM SHIFT TOWARD PRECISION DIAGNOSIS THROUGH PERSONALIZED MEDICINE
4.3.3. ADVANCEMENTS IN TECHNOLOGIES
4.4. MARKET CHALLENGES
4.4.1. HIGH INITIAL INVESTMENT AND MAINTENANCE COST
4.4.2. STRINGENT REGULATION FOR APPROVAL OF DEVICES
4.4.3. PRICING PRESSURE COUPLED WITH LACK OF PRODUCT DIFFERENTIATION
5. MARKET SEGMENTATION
5.1. MARKET BY PRODUCTS 2018-2026
5.1.1. ANTIBODIES
5.1.1.1. PRIMARY ANTIBODIES
5.1.1.2. SECONDARY ANTIBODIES
5.1.2. EQUIPMENT
5.1.2.1. SLIDE STAINING SYSTEMS
5.1.2.2. TISSUE MICROARRAYS
5.1.2.3. TISSUE PROCESSING SYSTEMS
5.1.2.4. SLIDE SCANNERS
5.1.2.5. OTHER EQUIPMENT’S
5.1.3. REAGENTS
5.1.3.1. HISTOLOGICAL STAINS
5.1.3.2. BLOCKING SERA AND REAGENTS
5.1.3.3. CHROMOGENIC SUBSTRATES
5.1.3.4. FIXATION REAGENTS
5.1.3.5. STABILIZERS
5.1.3.6. ORGANIC SOLVENTS
5.1.3.7. PROTEOLYTIC ENZYMES
5.1.3.8. DILUENTS
5.1.4. KITS
5.2. MARKET BY APPLICATIONS 2018-2026
5.2.1. DIAGNOSTICS
5.2.1.1. CANCER
5.2.1.2. INFECTIOUS DISEASES
5.2.1.3. CARDIOVASCULAR DISEASE
5.2.1.4. AUTOIMMUNE DISEASES
5.2.1.5. DIABETES MELLITUS
5.2.1.6. NEPHROLOGICAL DISEASES
5.2.2. DRUG TESTING
5.3. MARKET BY END-USERS 2018-2026
5.3.1. HOSPITALS AND DIAGNOSTIC LABORATORIES
5.3.2. RESEARCH INSTITUTES
5.3.3. OTHER END USERS
6. KEY ANALYTICS
6.1. IMMUNOHISTOCHEMISTRY ETYMOLOGY
6.2. VALUE CHAIN ANALYSIS
6.2.1. RAW MATERIAL SUPPLIERS
6.2.2. MANUFACTURERS
6.2.3. DISTRIBUTORS
6.2.4. END-USERS
6.3. OPPORTUNITY MATRIX
7. GEOGRAPHICAL ANALYSIS
7.1. EUROPE
7.1.1. THE UNITED KINGDOM
7.1.2. FRANCE
7.1.3. GERMANY
7.1.4. SPAIN
7.1.5. ITALY
7.1.6. RUSSIA
7.1.7. REST OF EUROPE
8. COMPANY PROFILES
8.1. ABBOTT LABORATORIES
8.1.1. COMPANY PROFILE
8.1.2. PRODUCT PORTFOLIO
8.1.3. SWOT ANALYSIS
8.1.4. STRATEGIC INITIATIVES
8.2. ABCAM PLC
8.2.1. COMPANY OVERVIEW
8.2.2. PRODUCT PORTFOLIO
8.2.3. STRATEGIC INITIATIVES
8.3. AGILENT TECHNOLOGIES, INC.
8.3.1. COMPANY OVERVIEW
8.3.2. PRODUCT PORTFOLIO
8.3.3. SCOT ANALYSIS
8.3.4. STRATEGIC INITIATIVES
8.4. BIOGENEX
8.4.1. COMPANY OVERVIEW
8.4.2. PRODUCT PORTFOLIO
8.4.3. STRATEGIC INITIATIVES
8.5. BIO-RAD LABORATORIES, INC.
8.5.1. COMPANY OVERVIEW
8.5.2. PRODUCT PORTFOLIO
8.5.3. SCOT ANALYSIS
8.5.4. STRATEGIC INITIATIVE
8.6. BIO SB
8.6.1. COMPANY OVERVIEW
8.6.2. PRODUCT PORTFOLIO
8.6.3. STRATEGIC INITIATIVES
8.7. CELL SIGNALING TECHNOLOGY, INC.
8.7.1. COMPANY OVERVIEW
8.7.2. PRODUCT PORTFOLIO
8.7.3. SCOT ANALYSIS
8.7.4. STRATEGIC INITIATIVES
8.8. DANAHER CORPORATION
8.8.1. COMPANY OVERVIEW
8.8.2. PRODUCT PORTFOLIO
8.8.3. SCOT ANALYSIS
8.8.4. STRATEGIC INITIATIVES
8.9. F. HOFFMANN-LA ROCHE AG
8.9.1. COMPANY OVERVIEW
8.9.2. PRODUCT PORTFOLIO
8.9.3. SCOT ANALYSIS:
8.9.4. STRATEGIC INITIATIVES
8.10. HISTOLOGIX
8.10.1. COMPANY OVERVIEW
8.10.2. PRODUCT PORTFOLIO
8.11. MERCK MILLIPORE
8.11.1. COMPANY OVERVIEW
8.11.2. PRODUCT PORTFOLIO
8.11.3. STRATEGIC INITIATIVES
8.12. PERKINELMER, INC.
8.12.1. COMPANY OVERVIEW
8.12.2. PRODUCT PORTFOLIO
8.12.3. SCOT ANALYSIS
8.12.4. STRATEGIC INITIATIVES
8.13. SIEMENS AG HEALTHCARE
8.13.1. COMPANY OVERVIEW
8.13.2. PRODUCT PORTFOLIO
8.13.3. SWOT ANALYSIS
8.13.4. STRATEGIC INITIATIVES
8.14. THERMO FISHER SCIENTIFIC INC.
8.14.1. COMPANY OVERVIEW
8.14.2. PRODUCT PORTFOLIO
8.14.3. SCOT ANALYSIS
8.14.4. STRATEGIC INITIATIVES



TABLE LIST
TABLE 1 EUROPE MARKET FOR IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
TABLE 2 CANCER MARKERS USED IN DIAGNOSIS AND TREATMENT
TABLE 3 POPULATION AGED 60 YEARS AND ABOVE
TABLE 4 POPULATION AGED 80 YEARS AND ABOVE
TABLE 5 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2018-2026 ($ MILLION)
TABLE 6 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN ANTIBODIES 2018-2026 ($ MILLION)
TABLE 7 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN ANTIBODIES BY TYPES 2018-2026 ($ MILLION)
TABLE 8 EUROPE ANTIBODIES MARKET IN PRIMARY ANTIBODIES 2018-2026 ($ MILLION)
TABLE 9 CLINICALLY IMPORTANT MONOCLONAL ANTIBODIES
TABLE 10 EUROPE ANTIBODIES MARKET IN SECONDARY ANTIBODIES GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 11 SECONDARY ANTIBODY SELECTION
TABLE 12 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT 2018-2026 ($ MILLION)
TABLE 13 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT BY TYPE 2018-2026 ($ MILLION)
TABLE 14 EUROPE EQUIPMENT MARKET IN SLIDE STAINING SYSTEMS 2018-2026 ($ MILLION)
TABLE 15 EUROPE EQUIPMENT MARKET IN TISSUE MICROARRAYS 2018-2026 ($ MILLION)
TABLE 16 EUROPE EQUIPMENT MARKET IN TISSUE PROCESSING SYSTEMS 2018-2026 ($ MILLION)
TABLE 17 EUROPE EQUIPMENT MARKET IN SLIDE SCANNERS 2018-2026 ($ MILLION)
TABLE 18 EUROPE EQUIPMENT MARKET IN OTHER EQUIPMENT’S 2018-2026 ($ MILLION)
TABLE 19 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS 2018-2026 ($ MILLION)
TABLE 20 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS BY TYPE 2018-2026 ($ MILLION)
TABLE 21 EUROPE REAGENTS MARKET IN HISTOLOGICAL STAINS 2018-2026 ($ MILLION)
TABLE 22 HISTOLOGY STAINS AND ITS CATEGORIES
TABLE 23 EUROPE REAGENTS MARKET IN BLOCKING SERA AND REAGENTS 2018-2026 ($ MILLION)
TABLE 24 EUROPE REAGENTS MARKET IN CHROMOGENIC SUBSTRATES 2018-2026 ($ MILLION)
TABLE 25 EUROPE REAGENTS MARKET IN FIXATION REAGENTS 2018-2026 ($ MILLION)
TABLE 26 COMMON FIXATIVES AND THEIR GENERAL TARGET ANTIGENS
TABLE 27 EUROPE REAGENTS MARKET IN STABILIZERS 2018-2026 ($ MILLION)
TABLE 28 EUROPE REAGENTS MARKET IN ORGANIC SOLVENTS 2018-2026 ($ MILLION)
TABLE 29 EUROPE REAGENTS MARKET IN PROTEOLYTIC ENZYMES 2018-2026 ($ MILLION)
TABLE 30 EUROPE REAGENTS MARKET IN DILUENTS 2018-2026 ($ MILLION)
TABLE 31 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN KITS 2018-2026 ($ MILLION)
TABLE 32 AVAILABLE KIT COMPONENTS FOR IHC OPTIMIZATION
TABLE 33 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 34 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTIC 2018-2026 ($ MILLION)
TABLE 35 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTIC BY TYPES 2018-2026 ($ MILLION)
TABLE 36 EUROPE DIAGNOSTIC MARKET IN CANCER 2018-2026 ($ MILLION)
TABLE 37 EUROPE DIAGNOSTIC MARKET IN INFECTIOUS DISEASES 2018-2026 ($ MILLION)
TABLE 38 EUROPE DIAGNOSTIC MARKET IN CARDIOVASCULAR DISEASE 2018-2026 ($ MILLION)
TABLE 39 EUROPE DIAGNOSTIC MARKET IN AUTOIMMUNE DISEASES 2018-2026 ($ MILLION)
TABLE 40 SELECTED INFECTIOUS ETIOLOGIES OF AUTOIMMUNE DISEASES
TABLE 41 EUROPE DIAGNOSTIC MARKET IN DIABETES MELLITUS 2018-2026 ($ MILLION)
TABLE 42 EUROPE DIAGNOSTIC MARKET IN NEPHROLOGICAL DISEASES 2018-2026 ($ MILLION)
TABLE 43 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN DRUG TESTING 2018-2026 ($ MILLION)
TABLE 44 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2018-2026 ($ MILLION)
TABLE 45 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN HOSPITALS AND DIAGNOSTIC LABORATORIES 2018-2026 ($ MILLION)
TABLE 46 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN RESEARCH INSTITUTES 2018-2026 ($ MILLION)
TABLE 47 CANCER RESEARCH PROGRAM
TABLE 48 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN OTHER END-USERS 2018-2026 ($ MILLION)
TABLE 49 IMMUNOHISTOCHEMISTRY USAGE IN FORENSIC PATHOLOGY
TABLE 50 ANTIBODIES MANUFACTURERS IN THE EUROPE IMMUNOHISTOCHEMISTRY MARKET
TABLE 51 EUROPE IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
TABLE 52 NUMBER OF PEOPLE LIVING AND DYING WITH CVD
TABLE 53 NUMBER OF DEATHS CAUSED BY CARDIOVASCULAR DISEASES IN GERMANY 2016
TABLE 54 DISEASES CAUSING PREMATURE DEATH IN GERMANY (2017)

FIGURES LIST
FIGURE 1 EUROPE MARKET FOR IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
FIGURE 2 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN ANTIBODIES 2018-2026 ($ MILLION)
FIGURE 3 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT 2018-2026 ($ MILLION)
FIGURE 4 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS 2018-2026 ($ MILLION)
FIGURE 5 PHASES OF HISTOLOGICAL STAINING
FIGURE 6 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN KITS 2018-2026 ($ MILLION)
FIGURE 7 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTIC 2018-2026 ($ MILLION)
FIGURE 8 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN DRUG TESTING 2018-2026 ($ MILLION)
FIGURE 9 INCIDENCE OF PATIENTS WITH CHRONIC DISEASES IN EUROPE 2005?2030
FIGURE 10 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN HOSPITALS AND DIAGNOSTIC LABORATORIES 2018-2026 ($ MILLION)
FIGURE 11 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN RESEARCH INSTITUTES 2018-2026 ($ MILLION)
FIGURE 12 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN OTHER END-USERS 2018-2026 ($ MILLION)
FIGURE 13 HISTORY OF IMMUNOHISTOCHEMISTRY
FIGURE 14 EUROPE IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
FIGURE 15 THE UNITED KINGDOM IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
FIGURE 16 FRANCE IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
FIGURE 17 GERMANY IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
FIGURE 18 SPAIN IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
FIGURE 19 ITALY IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
FIGURE 20 RUSSIA IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
FIGURE 21 REST OF EUROPE IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)

List of Tables

TABLE LIST
TABLE 1 EUROPE MARKET FOR IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
TABLE 2 CANCER MARKERS USED IN DIAGNOSIS AND TREATMENT
TABLE 3 POPULATION AGED 60 YEARS AND ABOVE
TABLE 4 POPULATION AGED 80 YEARS AND ABOVE
TABLE 5 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY PRODUCTS 2018-2026 ($ MILLION)
TABLE 6 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN ANTIBODIES 2018-2026 ($ MILLION)
TABLE 7 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN ANTIBODIES BY TYPES 2018-2026 ($ MILLION)
TABLE 8 EUROPE ANTIBODIES MARKET IN PRIMARY ANTIBODIES 2018-2026 ($ MILLION)
TABLE 9 CLINICALLY IMPORTANT MONOCLONAL ANTIBODIES
TABLE 10 EUROPE ANTIBODIES MARKET IN SECONDARY ANTIBODIES GEOGRAPHY 2018-2026 ($ MILLION)
TABLE 11 SECONDARY ANTIBODY SELECTION
TABLE 12 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT 2018-2026 ($ MILLION)
TABLE 13 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN EQUIPMENT BY TYPE 2018-2026 ($ MILLION)
TABLE 14 EUROPE EQUIPMENT MARKET IN SLIDE STAINING SYSTEMS 2018-2026 ($ MILLION)
TABLE 15 EUROPE EQUIPMENT MARKET IN TISSUE MICROARRAYS 2018-2026 ($ MILLION)
TABLE 16 EUROPE EQUIPMENT MARKET IN TISSUE PROCESSING SYSTEMS 2018-2026 ($ MILLION)
TABLE 17 EUROPE EQUIPMENT MARKET IN SLIDE SCANNERS 2018-2026 ($ MILLION)
TABLE 18 EUROPE EQUIPMENT MARKET IN OTHER EQUIPMENT’S 2018-2026 ($ MILLION)
TABLE 19 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS 2018-2026 ($ MILLION)
TABLE 20 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN REAGENTS BY TYPE 2018-2026 ($ MILLION)
TABLE 21 EUROPE REAGENTS MARKET IN HISTOLOGICAL STAINS 2018-2026 ($ MILLION)
TABLE 22 HISTOLOGY STAINS AND ITS CATEGORIES
TABLE 23 EUROPE REAGENTS MARKET IN BLOCKING SERA AND REAGENTS 2018-2026 ($ MILLION)
TABLE 24 EUROPE REAGENTS MARKET IN CHROMOGENIC SUBSTRATES 2018-2026 ($ MILLION)
TABLE 25 EUROPE REAGENTS MARKET IN FIXATION REAGENTS 2018-2026 ($ MILLION)
TABLE 26 COMMON FIXATIVES AND THEIR GENERAL TARGET ANTIGENS
TABLE 27 EUROPE REAGENTS MARKET IN STABILIZERS 2018-2026 ($ MILLION)
TABLE 28 EUROPE REAGENTS MARKET IN ORGANIC SOLVENTS 2018-2026 ($ MILLION)
TABLE 29 EUROPE REAGENTS MARKET IN PROTEOLYTIC ENZYMES 2018-2026 ($ MILLION)
TABLE 30 EUROPE REAGENTS MARKET IN DILUENTS 2018-2026 ($ MILLION)
TABLE 31 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN KITS 2018-2026 ($ MILLION)
TABLE 32 AVAILABLE KIT COMPONENTS FOR IHC OPTIMIZATION
TABLE 33 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY APPLICATION 2018-2026 ($ MILLION)
TABLE 34 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTIC 2018-2026 ($ MILLION)
TABLE 35 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN DIAGNOSTIC BY TYPES 2018-2026 ($ MILLION)
TABLE 36 EUROPE DIAGNOSTIC MARKET IN CANCER 2018-2026 ($ MILLION)
TABLE 37 EUROPE DIAGNOSTIC MARKET IN INFECTIOUS DISEASES 2018-2026 ($ MILLION)
TABLE 38 EUROPE DIAGNOSTIC MARKET IN CARDIOVASCULAR DISEASE 2018-2026 ($ MILLION)
TABLE 39 EUROPE DIAGNOSTIC MARKET IN AUTOIMMUNE DISEASES 2018-2026 ($ MILLION)
TABLE 40 SELECTED INFECTIOUS ETIOLOGIES OF AUTOIMMUNE DISEASES
TABLE 41 EUROPE DIAGNOSTIC MARKET IN DIABETES MELLITUS 2018-2026 ($ MILLION)
TABLE 42 EUROPE DIAGNOSTIC MARKET IN NEPHROLOGICAL DISEASES 2018-2026 ($ MILLION)
TABLE 43 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN DRUG TESTING 2018-2026 ($ MILLION)
TABLE 44 EUROPE IMMUNOHISTOCHEMISTRY MARKET BY END-USERS 2018-2026 ($ MILLION)
TABLE 45 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN HOSPITALS AND DIAGNOSTIC LABORATORIES 2018-2026 ($ MILLION)
TABLE 46 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN RESEARCH INSTITUTES 2018-2026 ($ MILLION)
TABLE 47 CANCER RESEARCH PROGRAM
TABLE 48 EUROPE IMMUNOHISTOCHEMISTRY MARKET IN OTHER END-USERS 2018-2026 ($ MILLION)
TABLE 49 IMMUNOHISTOCHEMISTRY USAGE IN FORENSIC PATHOLOGY
TABLE 50 ANTIBODIES MANUFACTURERS IN THE EUROPE IMMUNOHISTOCHEMISTRY MARKET
TABLE 51 EUROPE IMMUNOHISTOCHEMISTRY MARKET 2018-2026 ($ MILLION)
TABLE 52 NUMBER OF PEOPLE LIVING AND DYING WITH CVD
TABLE 53 NUMBER OF DEATHS CAUSED BY CARDIOVASCULAR DISEASES IN GERMANY 2016
TABLE 54 DISEASES CAUSING PREMATURE DEATH IN GERMANY (2017)

Companies Mentioned

1. ABBOTT LABORATORIES
2. ABCAM PLC
3. AGILENT TECHNOLOGIES, INC.
4. BIOGENEX
5. BIO-RAD LABORATORIES, INC.
6. BIO SB
7. CELL SIGNALING TECHNOLOGY, INC.
8. DANAHER CORPORATION
9. F. HOFFMANN-LA ROCHE AG
10. HISTOLOGIX
11. MERCK MILLIPORE
12. PERKINELMER, INC.
13. SIEMENS AG HEALTHCARE
14. THERMO FISHER SCIENTIFIC INC.

 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る